P53 and BCL-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy

Journal of Urology

Volumn 162, Issue 6, 1999, Pages 2040-2045

  Stackhouse, George B ^b   Sesterhenn, Isabell A ^b   Bauer, John J ^b   Mostofi, F Kash ^b   Connelly, Roger R ^b   Srivastava, Shiv K ^b   Moul, Judd W ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NONE

Author keywords

C bcl 2 proteins; Neoplasm staging; Prostate neoplasms; Prostatectomy; Protein p53

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY;

EID: 0032699925     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)68095-0     Document Type: Article

References (36)

1. Landis, S. H., Murray, T., Bolden, S. and Wingo, P. A.: Cancer Statistics, 1998. CA, 48: 6, 1998.
2. Wilt, T. J. and Brawer, M. K.: The prostate cancer intervention versus observation trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J. Urol., 152: 1910, 1994.
3. Woolf, S. H.: Screening for prostate cancer. Lancet, 349: 1098, 1997.
4. Coley, C. M., Barry, M. J., Fleming, C., Fahs, M. C. and Mulley, A. G.: Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians. Ann. Intern. Med., 126: 468, 1997.
5. Bostwick, D. G.: Grading prostate cancer. Amer. J. Clin. Path. 102: S3, 1994.
6. Murphy, G. P., Busch, C., Abrahamson, P. A., Epstein, J. I., McNeal, J. E., Miller, G. J., Mostofi, F. K., Nagle, R. B., Nordling, S. and Parkinson, C.: Histopathology of localized prostate cancer. Consensus conference on diagnosis and prognostic parameters in localized prostate cancer. Stockholm, Sweden, May 12-13, 1993. Scand. J. Urol. Nephrol., 162: 7, 1994.
7. Murphy, G. P., Mettlin, C., Menck, H., Winchester, D. P. and Davidson, A. M.: National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer. J. Urol., 152: 1817, 1994.
8. Trapasso, J. G., deKernion, J. B., Smith, R. B. and Dorey, F.: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J. Urol., 152: 1821, 1994.
9. Catalona, W. J. and Smith, D. S.: 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J. Urol., 152: 1837, 1994.
10. Paulson, D. F.: Impact of radical prostatectomy in the management of clinically localized disease. J. Urol., 152: 1826, 1994.
11. Zincke, H., Oesterling, J. E. Blute, M. L., Bergstralh, E. J., Myers, R. P. and Barrett, D. M.: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J. Urol., 152: 1850, 1994.
12. Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S. and Moul, J. W.: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J. Urol., 156: 1511, 1996.
13. Matsushima, H., Kitamura, T., Goto, T., Hosaka, Y., Homma, T. and Kawabe, K.: Combined analysis with bcl-2 and p-53 Immunostaining predicts poorer prognosis in prostatic carcinoma. J. Urol., 158: 2278, 1997.
14. Baker, S. J., Markowitz, S. Fearon, E. R., Willson, J. K. and Vogelstein, B.: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science, 249: 912, 1990.
15. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B. and Craig, R. W.: Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304, 1991.
16. Lowe, S. W., Schmittt, E. M., Smith, S. W., Osborne, B. A. and Jacks, T.: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature, 362: 84, 1993.
17. Levine, A. J., Momand, J. and Finlay, C. A.: The p53 tumor suppresser gene. Nature, 351: 453, 1991.
18. Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C. C.: p53 Mutations in human cancers. Science, 253: 49, 1991.
19. Voeller, H. J., Sugars, L. Y., Pretlow, T. and Gelmann, E. P.: p53 Oncogene mutations in human prostate cancer specimens. J. Urol., 151: 492, 1994.
20. Van Veldhuizen, P. J., Sadasivan, R, Garcia, F., Austenfeld. M. S. and Stephens, R. L.: Mutant p53 expression in prostate carcinoma. Prostate, 22: 23, 1993.
21. Mirchandani, D., Zheng, J., Miller, G. J., Ghosh, A. K., Shibata, D. K. Cote, R. J. and Roy-Burman, P.: Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Amer. J. Path., 147: 92, 1995.
22. Heidenberg, H. B., Sesterhenn, I. A., Gaddipati, J. P., Weghorst, C. M., Buzard, G. S., Moul, J. W. and Srivastava, S.: Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J. Urol., 154: 414, 1995.
23. Bubendorf, L., Sauter, G., Moch, H., Jordan, P., Blochlinger, A., Gasser, T. C. and Mihatsch, M. J.: Prognostic significance of bcl-2 in clinically localized prostate cancer. Amer. J. Path., 148: 1557, 1996.
24. Shurbaji, M. S., Kalbfleisch, J. H. and Thurmond, T. S.: Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum. Path., 26: 106, 1995.
25. Grignon, D. J., Caplan, R. Sarkar, F. H., Lawton, C. A., Hammond, E. H., Pilepich, M. V., Forman, J. D., Mesic, J., Fu, K. K., Abrams, R. A., Pajak, T. F., Shipley, W. U. and Cox, J. D.: p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J. Natl. Cancer Inst., 89: 158, 1997.
26. Stattin, P., Bergh, A., Karlberg, L., Nordgren, H. and Damber, J. E: p53 immunoreactivity as prognostic marker for cancer-specific survival in prostate cancer. Eur. Urol., 30: 65, 1996.
27. Vesalainen, S. L., Lipponen, P. K, Taja, M. T., Alhava, E. M. and Syrjanen, K. J. K. J.: Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1-2 M0 prostatic adenocarcinoma. Int. J. Cancer, 58: 303, 1994.
28. Brooks, J. D., Bova, G. S., Ewing, C. M., Piantadosi, S., Carter, B. S., Robinson, J. C., Epstein, J. I. and Isaacs, W. B.: An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res., 56: 3814, 1996.
29. Sentman, C. L, Shutter, J. R. Hockenbery, D., Kanagawa, O. and Korsmeyer, S. J.: bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell. 67: 879, 1991.
30. Bakhshi, A., Jensen, J. P., Goldman, P., Wright, J. J., McBride, O. W., Epstein, A. L. and Korsmeyer, S. J.: Cloning the chromosomal breakpoint of t(14: 18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell, 14: 889, 1984.
31. McDormell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C., Chung, L. W. K., Hsieh, J. T., Tu, S. M. and Campbell, M. L.: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940, 1992.
32. Colombel, M., Symmans, F., Gil, S., O'Toole, K., Chopin, D., Benson, M., Olsson, C., Korsmeyer, S. and Buttyan, R.: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers. Amer. J. Path., 143: 390, 1993.
33. Huang, A., Gandour-Edwards, R., Rosenthal, S. A., Siders, D. B., Deitch, A. D. and Devere White, R.: W.:P53 and bcl-2 Immunohistochemical alteration in prostate cancer treated with radiation therapy. Urology, 51: 346, 1998.
34. Grossfeld, G. D., Olumi, A. F., Connolly, J. A., Chew, K., Gibney, J., Bhargava, V., Waldman, F. M. and Carroll, P. R.: Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in KI-67 labeling index, p53, and bcl-2 immunoreactivity. J. Urol., 159: 1437, 1998.
35. Byrne, R. L., Home, C. H., Robinson, M. C., Autzen, P., Apakama, I., Bishop, R. I., Neal, D. E. and Hamdy, F. C.: The expression of waf-1, p53, and bcl-2 in prostatic adenocarcinoma. Brit. J. Urol., 79: 190, 1997.
36. Moul, J. W., Connelly, R. R., Mooneyhan, R. M., Zhang, W., Sesterhenn, I. A., Mostofi, F. K. and McLeod, D. G.: Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients. J. Urol., 162: 394, 1999.